A prospective study comparing incision and curettage with intralesional injection of triamcinolone acetonide for treating chalazia in South Indian population

---

Original Article

Author Details : Manjunath Natarajan, Bhavna Govindaraj*

Volume : 8, Issue : 1, Year : 2022

Article Page : 12-15

https://doi.org/10.18231/j.ijooo.2022.002

Suggest article by email

Get Permission

---

Abstract

Purpose: To compare the results and recurrences of incision and curettage with intralesional triamcinolone acetonide (TA) in treating chalazia.
Materials and Methods: Patients with chalazia were treated with either intralesional injection of triamcinolone acetonide or incision and curettage (I & C) by randomisation into 2 different groups. The patients were then followed up after 2 weeks and then 3 months post-procedure to assess the size. A size reduction of 90% was considered as adequately treated for the purposes of this study.
Results: Out of a total of 60 patients selected for the study, 30 patients underwent intralesional triamcinolone injections & the other 30 patients incision & curettage for their chalazia respectively. Adequate treatment thresholds were achieved in 24% patients (80%) in the Triamcinolone Acetonide group and 29 patients (96.67%) in the incision & curettage group. Recurrence of the lesion was seen in 9 patients (30%) in the triamcinolone acetonide group & 2 patients (6.67%) in the incision & curettage group. Intraocular pressure & visual acuity remained unaltered during follow-ups in both groups.
Conclusions: We found both methods to have good success rates. The I & C group had lesser recurrences and higher success rates when compared to the TA group.
 
Keywords: Chalazion, Triamcinolone acetonide, Incision & Curettage.

How to cite : Natarajan M, Govindaraj B, A prospective study comparing incision and curettage with intralesional injection of triamcinolone acetonide for treating chalazia in South Indian population. IP Int J Ocul Oncol Oculoplasty 2022;8(1):12-15

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.